Stock Taper
Lucid Diagnostics Inc., a New York-based subsidiary of PAVmed, develops diagnostic tools like EsoGuard and EsoCheck to detect esophageal precancer and cancer in patients with GERD.

The EsoGuard Esophageal DNA Test is a non-invasive, FDA-approved screening tool for early detection of esophageal precancer in at-risk GERD patients, enabling earlier intervention and reducing reliance on invasive endoscopy.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
AVR | $9.04 | COMPARE |
IRD | $4.67 | COMPARE |
RCEL | $11.20 | COMPARE |
APYX | $3.05 | COMPARE |
SEER | $1.95 | COMPARE |
OWLT | $4.98 | COMPARE |
RPID | $1.31 | COMPARE |
SCLX | $5.42 | COMPARE |